// App-Quantinova.ai

603 : Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Dafna D Gladman

  • Arthur Kavanaugh

  • Priscila Nakasato

  • Benoit Guerette

  • Lichen Teng

  • Peter Nash

Medical Centers

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Krembil Research Institute, Toronto Western Hospital, Toronto, Canada

  • University of California, San Diego School of Medicine, La Jolla, CA

  • Celgene Corporation, Summit, NJ

  • The University of Queensland, Brisbane, Australia

Locations

  • United States

  • Canada

  • Australia

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • N/A

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved